Navigation Links
Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference

ABBOTT PARK, Ill., Aug. 31 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) will present at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, Sept. 14, 2009. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a presentation on the company at 8:10 a.m. Central time.

A live audio webcast of the presentation will be accessible through Abbott's Investor Relations Web site at An archived edition of the presentation will be available later that day.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
2. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
3. Health Canada Approves Abbotts XIENCE V(R) Drug Eluting Stent
4. Abbott Testifies Before U.S. Congress on Role of Private Sector in Advancing Science Education
5. Abbott to Acquire Nutrition Businesses, Expanding Presence in India
6. Abbott and Medtronic Reach Agreement on Global Patent Disputes
7. NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test
8. Abbott Introduces Molecular Diagnostic System Intended for Broad Identification of Infectious Agents
9. Abbott Launches New Instrument to Complete Family of ARCHITECT Immunochemistry Analyzers
10. Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009
11. Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal(R) Vet, a New Chemotherapeutic Agent for Dogs
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: